Company intelligence / Profile preview

Kygent Pharmaceutical

Ownership: Private
Development stage: Preclinical

Overview

Kygent has developed KY‑001, an oral small-molecule inhibitor targeting the YAP/TAZ–TEAD interaction in the Hippo pathway. In April 2025, KY‑001 received FDA Orphan Drug Designation for malignant pleural mesothelioma and previously received clinical trial application approval from China's CDE. The company also reports discovery of new DNMT1 inhibitors useful in cancer treatment but these appear to be at an earlier stage[3][1].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Partnerships

SDM Bioservices supported regulatory submissions and orphan drug designation process for KY‑001 with the FDA[3]

Beyond the preview

Go deeper on Kygent Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kygent Pharmaceutical.

Explore the full profile